Immunotherapy with chemotherapy for advanced pancreatic cancer
Part of Cancer, Digestive system, Hormones & metabolism, Infections clinical trials.
This trial tests a new type of immunotherapy (called Lm-LLO-TT) combined with a standard chemotherapy drug (gemcitabine) for people with advanced pancreatic cancer that cannot be removed by surgery. The goal is to see if this combination is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older and have advanced pancreatic cancer that cannot be surgically removed.
- You must have had at least one prior chemotherapy treatment, or have a medical reason you cannot take the standard chemotherapies.
- Your overall health should be reasonably good (able to care for yourself, up and about more than half the day).
- You must not have severe heart failure, kidney failure, liver scarring, or a large amount of belly fluid.
- You must not have metal implants like pacemakers, artificial heart valves, or joint replacements.
- You must not have had certain vaccines, steroids, or antibiotics within a few weeks before starting the trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new targeted drug (LM-302) combined with a standard chemotherapy drug (gemcitabine) for people with advanced pancreatic cancer that has progressed after initial treatment. The goal is to see if this combination can slow down or shrink the cancer.
This trial tests a new immune cell therapy (EGFRBi armed PBMC) for people with advanced pancreatic cancer that can't be removed by surgery. It aims to see if this treatment can help control the cancer after you've already tried at least one type of chemotherapy and your disease is stable or better.
This trial tests a new kind of immunotherapy for pancreatic cancer that has not been removed by surgery or has spread. It aims to see if the treatment can help shrink or control the cancer, and you may be eligible whether you have had previous chemotherapy or not.
This trial tests a new type of vaccine (called ONVAX-01) combined with an immunotherapy drug and chemotherapy for advanced pancreatic cancer. The goal is to see if this combination can help your immune system fight the cancer more effectively than the usual treatments alone.
This trial tests a combination of immunotherapy drugs (targeting CD40 and other immune cells) as a maintenance treatment for people with advanced pancreatic cancer that has not grown or has shrunk after initial chemotherapy. The goal is to see if this approach can keep the cancer from progressing longer.
This trial tests a new drug (OMTX705) combined with standard chemotherapy (gemcitabine/nab-paclitaxel) and an immunotherapy (tislelizumab) for people with advanced pancreatic cancer. It may be an option if you have had little or no prior chemotherapy.
Hear when a new Pancreatic cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.